Aspira Women's Health Files 8-K with Material Agreement

TL;DR

Aspira Women's Health filed an 8-K on Aug 2nd for a material agreement. Check it out.

AI Summary

On August 2, 2024, Aspira Women's Health Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.

Why It Matters

This filing indicates a significant business event or financial update for Aspira Women's Health Inc., which could impact investors and stakeholders.

Risk Assessment

Risk Level: low — This is a standard 8-K filing reporting a material definitive agreement and financial statements, not indicating immediate operational or financial distress.

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• August 02, 2024 (date) — Date of earliest event reported
• Vermillion, Inc. (company) — Former company name
• Ciphergen Biosystems Inc (company) — Former company name
• Abiotic Systems (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• Austin, Texas (location) — Business address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AWH The Nasdaq Stock Mark
• $4,450,000 — aving an aggregate sales price of up to $4,450,000, from time to time, through an "at the

Filing Documents

• awh-20240802.htm (8-K) — 48KB
• awh-ex1_1.htm (EX-1.1) — 375KB
• awh-ex5_1.htm (EX-5.1) — 31KB
• img170348524_0.jpg (GRAPHIC) — 14KB
• 0000950170-24-090145.txt ( ) — 651KB
• awh-20240802.xsd (EX-101.SCH) — 25KB
• awh-20240802_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 2, 2024, Aspira Women's Health Inc. (the " Company ") entered into an At The Market Offering Agreement (the " ATM Agreement ") with H.C. Wainwright & Co., LLC (" Wainwright "), to sell shares of our common stock, par value $0.001 per share, (the " Shares ") having an aggregate sales price of up to $4,450,000, from time to time, through an "at the market offering" program under which Wainwright will act as sales agent. The sales, if any, of the Shares made under the ATM Agreement will be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. We will pay Wainwright a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and have agreed to provide Wainwright with customary indemnification and contribution rights. We will also reimburse Wainwright for certain specified expenses in connection with entering into the ATM Agreement. The ATM Agreement contains customary representations and warranties and conditions to the sale of the Shares pursuant thereto. We are not obligated to sell any of the Shares under the ATM Agreement and may at any time suspend solicitation and offers thereunder. The offering of Shares pursuant to the ATM Agreement will terminate on the earlier of (1) the sale, pursuant to the ATM Agreement, of Shares having an aggregate offering price of $4,450,000 and (2) the termination of the ATM Agreement by either us or Wainwright, as permitted therein. The Shares will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-278867) filed by the Company with the SEC on April 22, 2024 and declared effective by the SEC on April 25, 2024. Concurrently herewith, we are filing a prospectus supplement (the "Prospectus Supplement"), dated August 2, 2024, with the U.S. Securities and Exchange Commission in connection with the offer and sa

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 1.1 At The Market Offering Agreement between Aspira Women's Health Inc. and H.C. Wainwright & Co., LLC dated August 2, 2024 5.1 Opinion of Sheppard, Mullin, Richter & Hampton LLP 23.1 Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: August 2, 2024 By: /s/ Nicole Sandford Nicole Sandford, Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR